PTC Therapeutics completes enrollment in muscular dystrophy trial
Accrual was completed two months ahead of schedule. The company has also announced that PTC124 has been issued the generic name, ataluren. The pivotal trial is ongoing at
Akeso has received approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis.